Phathom Pharmaceuticals Stock EBITDA

PHAT Stock

USD 8.87 0.10 1.11%

Phathom Pharmaceuticals fundamentals help investors to digest information that contributes to Phathom Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Phathom Stock. The fundamental analysis module provides a way to measure Phathom Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Phathom Pharmaceuticals stock.

		Last Reported	Projected for Next Year
	EBITDA	-159 M	-167 M

EBITDA is likely to drop to about (167 M) in 2024.

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Phathom Pharmaceuticals Company EBITDA Analysis

Phathom Pharmaceuticals' EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.

EBITDA

Revenue

-

Basic Expenses

More About EBITDA | All Equity Analysis

Current Phathom Pharmaceuticals EBITDA

(159.05 M)

Most of Phathom Pharmaceuticals' fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Phathom Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Phathom EBITDA Driver Correlations

Understanding the fundamental principles of building solid financial models for Phathom Pharmaceuticals is extremely important. It helps to project a fair market value of Phathom Stock properly, considering its historical fundamentals such as EBITDA. Since Phathom Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Phathom Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Phathom Pharmaceuticals' interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Net Tangible Assets	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Capital Surpluse	Total Liab	Net Invested Capital	Short Long Term Debt	Total Current Assets	Net Working Capital	Short Term Debt	Long Term Debt	Long Term Debt Total	Common Stock	Property Plant Equipment	Net Receivables
Total Assets		0.25	0.26	0.86	-0.95	-0.87	0.84	0.94	0.77	0.74	0.94	1.0	1.0	0.07	0.77	0.72	0.85	0.71	0.62
Total Stockholder Equity	0.25		1.0	-0.03	-0.36	0.18	0.09	0.22	-0.38	0.8	0.31	0.26	0.27	0.43	-0.35	-0.27	-0.25	-0.18	-0.41
Net Tangible Assets	0.26	1.0		-0.02	-0.38	0.17	0.1	0.23	-0.36	0.81	0.32	0.28	0.29	0.42	-0.34	-0.26	-0.24	-0.17	-0.39
Current Deferred Revenue	0.86	-0.03	-0.02		-0.78	-0.96	0.9	0.93	0.85	0.55	0.87	0.86	0.84	0.1	0.88	0.87	0.87	0.7	0.59
Net Debt	-0.95	-0.36	-0.38	-0.78		0.78	-0.77	-0.85	-0.72	-0.81	-0.84	-0.96	-0.96	-0.14	-0.6	-0.52	-0.73	-0.63	-0.63
Retained Earnings	-0.87	0.18	0.17	-0.96	0.78		-0.8	-0.9	-0.94	-0.44	-0.84	-0.86	-0.86	0.14	-0.94	-0.89	-0.91	-0.72	-0.73
Accounts Payable	0.84	0.09	0.1	0.9	-0.77	-0.8		0.84	0.7	0.54	0.8	0.83	0.79	0.46	0.72	0.7	0.81	0.86	0.47
Capital Surpluse	0.94	0.22	0.23	0.93	-0.85	-0.9	0.84		0.72	0.73	0.99	0.94	0.93	0.05	0.82	0.83	0.8	0.66	0.45
Total Liab	0.77	-0.38	-0.36	0.85	-0.72	-0.94	0.7	0.72		0.24	0.64	0.76	0.75	-0.21	0.88	0.76	0.91	0.72	0.91
Net Invested Capital	0.74	0.8	0.81	0.55	-0.81	-0.44	0.54	0.73	0.24		0.76	0.75	0.75	0.29	0.24	0.27	0.32	0.22	0.11
Short Long Term Debt	0.94	0.31	0.32	0.87	-0.84	-0.84	0.8	0.99	0.64	0.76		0.94	0.94	0.05	0.76	0.79	0.75	0.63	0.37
Total Current Assets	1.0	0.26	0.28	0.86	-0.96	-0.86	0.83	0.94	0.76	0.75	0.94		1.0	0.08	0.76	0.72	0.85	0.71	0.61
Net Working Capital	1.0	0.27	0.29	0.84	-0.96	-0.86	0.79	0.93	0.75	0.75	0.94	1.0		0.02	0.75	0.71	0.83	0.67	0.61
Short Term Debt	0.07	0.43	0.42	0.1	-0.14	0.14	0.46	0.05	-0.21	0.29	0.05	0.08	0.02		-0.24	-0.19	-0.05	0.29	-0.27
Long Term Debt	0.77	-0.35	-0.34	0.88	-0.6	-0.94	0.72	0.82	0.88	0.24	0.76	0.76	0.75	-0.24		0.97	0.94	0.67	0.68
Long Term Debt Total	0.72	-0.27	-0.26	0.87	-0.52	-0.89	0.7	0.83	0.76	0.27	0.79	0.72	0.71	-0.19	0.97		0.87	0.61	0.49
Common Stock	0.85	-0.25	-0.24	0.87	-0.73	-0.91	0.81	0.8	0.91	0.32	0.75	0.85	0.83	-0.05	0.94	0.87		0.78	0.79
Property Plant Equipment	0.71	-0.18	-0.17	0.7	-0.63	-0.72	0.86	0.66	0.72	0.22	0.63	0.71	0.67	0.29	0.67	0.61	0.78		0.55
Net Receivables	0.62	-0.41	-0.39	0.59	-0.63	-0.73	0.47	0.45	0.91	0.11	0.37	0.61	0.61	-0.27	0.68	0.49	0.79	0.55

Click cells to compare fundamentals

In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.

Competition

Predict Phathom Pharmaceuticals

Ebitda Over Time

Phathom Ebitda

Ebitda

(167 Million)

At this time, Phathom Pharmaceuticals' EBITDA is comparatively stable compared to the past year.

According to the company disclosure, Phathom Pharmaceuticals reported earnings before interest,tax, depreciation and amortization of (159.05 Million). This is 118.13% lower than that of the Pharmaceuticals sector and 258.8% lower than that of the Health Care industry. The ebitda for all United States stocks is 104.08% higher than that of the company.

Phathom EBITDA Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Phathom Pharmaceuticals' direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Phathom Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Phathom Pharmaceuticals by comparing valuation metrics of similar companies.

Phathom Pharmaceuticals is currently under evaluation in ebitda category among its peers.

Phathom Pharmaceuticals Current Valuation Drivers

We derive many important indicators used in calculating different scores of Phathom Pharmaceuticals from analyzing Phathom Pharmaceuticals' financial statements. These drivers represent accounts that assess Phathom Pharmaceuticals' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Phathom Pharmaceuticals' important valuation drivers and their relationship over time.

	2019	2020	2021	2022	2023	2024 (projected)
Market Cap	770.0M	1.1B	727.8M	438.9M	468.3M	682.0M
Enterprise Value	549.8M	865.4M	635.9M	380.6M	225.9M	214.6M

Phathom Pharmaceuticals ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Phathom Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Phathom Pharmaceuticals' managers, analysts, and investors.

Environmental

Governance

Social

Phathom Pharmaceuticals Institutional Holders

Institutional Holdings refers to the ownership stake in Phathom Pharmaceuticals that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Phathom Pharmaceuticals' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Phathom Pharmaceuticals' value.

		Shares
Checkpoint Capital Lp	2024-09-30	1.5 M
Federated Hermes Inc	2024-09-30	1.4 M
Fmr Inc	2024-09-30	1.3 M
Portolan Capital Management, Llc	2024-06-30	1.1 M
Gw&k Investment Management, Llc	2024-09-30	1.1 M
Catalys Pacific Llc	2024-09-30	1.1 M
683 Capital Management Llc	2024-09-30	1 M
Saturn V Capital Management Llc	2024-09-30	874.6 K
Propel Bio Management Llc	2024-06-30	869.9 K
Medicxi Ventures Management (jersey) Ltd	2024-09-30	7.5 M
Jennison Associates Llc	2024-09-30	5.9 M

Phathom Fundamentals

	Return On Equity	-34.89
	Return On Asset	-0.58
	Operating Margin	(4.33) %
	Current Valuation	455.08 M
	Shares Outstanding	68.38 M
	Shares Owned By Insiders	7.69 %
	Shares Owned By Institutions	92.31 %
	Number Of Shares Shorted	14.66 M
	Price To Book	25.37 X
	Price To Sales	23.35 X
	Revenue	682 K
	EBITDA	(159.05 M)
	Net Income	(201.59 M)
	Cash And Equivalents	207.39 M
	Cash Per Share	5.39 X
	Total Debt	139.03 M
	Debt To Equity	2.43 %
	Current Ratio	9.93 X
	Book Value Per Share	(2.74) X
	Cash Flow From Operations	(137.58 M)
	Short Ratio	8.61 X
	Earnings Per Share	(5.74) X
	Target Price	25.29
	Number Of Employees	452
	Beta	0.72
	Market Capitalization	613.35 M
	Total Asset	413.84 M
	Retained Earnings	(928.68 M)
	Working Capital	358.65 M
	Net Asset	413.84 M

About Phathom Pharmaceuticals Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Phathom Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Phathom Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Phathom Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Phathom Stock Analysis

When running Phathom Pharmaceuticals' price analysis, check to measure Phathom Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Phathom Pharmaceuticals is operating at the current time. Most of Phathom Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Phathom Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Phathom Pharmaceuticals' price. Additionally, you may evaluate how the addition of Phathom Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC